Eli Lilly (LLY) has asked European nations to discard clawback taxes on drug sales, Hannah Kuchler of The Financial Times reports. As the Trump administration pushes for a policy that would lower drug prices in the U.S. to match the cheapest levels in other developed nations, Lilly CEO David Ricks said the company will lower U.S. costs while raising them in Europe to equalize the drug prices. The pharma industry has been dealing with UK’s clawback tax, where a certain percent of revenue above a cap is paid back to the government, but Risks believes the system should not exist in any country.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LLY:
- Eli Lilly (LLY) to Build $3 Billion European Plant to Manufacture Weight-Loss Pill
- Eli Lilly’s New Study on Brenipatide: A Potential Game-Changer in Smoking Cessation
- Eli Lilly to build new $3B facility in Katwijk, the Netherlands
- Eli Lilly’s Earnings Call: Robust Growth and Strategic Wins
- Eli Lilly (LLY) Says Weight-Loss Pill a Candidate for Fast-Track Approval